IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Sven SCHREDER et al.

Serial No.: Not Yet Assigned Group Art Unit: 1614

Filed: September 12, 2003 Examiner: P. Spivack

For: PHARMACEUTICAL PREPARATION

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

\boxtimes	Under 37 C.F.R. § 1.97(b), no fee or statement is required for filing this disclosure statement is filed:			
	\boxtimes		three months of the filing date of a national application other than a CPA § 1.53(d);	
			three months of the actual filing date of the national phase of a PCT ration; OR	
		before RCE).	the mailing of a first substantive office action (including after filing of an	
			.R. § 1.97(c), this information disclosure statement is filed after the periods 7 C.F.R. § 1.97(b), but before the mailing date of:	
			a final rejection under 37 C.F.R. 1.113;	
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR	
			a notice of allowance under 37 C.F.R. § 1.311; and	

		is acco	ompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p).
			R. § 1.97(d), this information disclosure statement is filed after the mailing lowing actions which have not been withdrawn:
			a final action under 37 C.F.R. § 1.113;
			termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2) OR
			a notice of allowance under 37 C.F.R. § 1.311;
	AND	is filed	on or before payment of the issue fee; AND is accompanied by:
			the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).
State	ments U	nder 37	C.F.R. 1.97(e)
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.
Cited	Materia	ıls	
	\boxtimes	ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120 or application Serial No. 09/700,421, on Form 892 by the Examiner and/o 1449 by the applicant; see 37 C.F.R. § 1.98(d).
		-	s of materials listed but not attached were cited in an international search dated
		Copie	s of the materials listed are attached (except for the foregoing).

Non-E	nglish l	Language References
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art
		O = non-written disclosure
		P = intercalated document
		T = document cited to understand the theory or principle underlying the invention
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date
		D = cited in the application
		L = cited for another reason
		& = publication of member of same patent family
		Translation of other relevant information on foreign search report
		[insert necessary translation here]
Other	Informa	<u>ntion</u>
Payme	ent of Fe	ees Due (If Any):
		ck for \$ covering the fee identified above is attached.
	Please	charge to Deposit Account No. 13-3402 \$ for the fee identified above.

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Harry B. Shubin, Reg. No. 32,004 Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza I 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: MERCK-2168D1

Date: September 15, 2003

HBS:jmj

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					Complete if Known			
					Application Number	Not Yet Assigned		
I	NFO	RMATION	N DISC	LOSURE	Filing Date	September 12, 2003		
5	STAT	TEMENT	3Y APF	LICANT	.First Named Inventor	Sven Schreder et al.		
					Group Art Unit	1614		
		(use as many s	heets as ne	cessary)	Examiner Name	P. Spivack		
s	heet	1	of	1	Attorney Docket Number	MERCK-2168D1		

		<u>U.S.</u>	PATENT DOCUMENTS	
Examiner Initials *	Cite No.1	U.S. Patent Document Kind Coo Number (if know	Name of Catalog of Applicant	Date of Publication of Cited Document MM-DD-YYYY
		5,225,204	Papadimitriou	7-6-1993
		3,808,332	Reynolds	4-30-1974
		3,621,096	Prange et al.	11-16-1971

			oreign Patent Docur	ment		Date of Publication of	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	Cite No.1	Office ³	Number⁴	Kind Code ⁵ (<i>if known</i>)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	т6
		GB	1,296,510		Horster	11-15-1972		
		DE	195 41 128		· · · · · · · · · · · · · · · · · · ·	4-30-1997		
		GB	1,180,574					
				<u> </u>				

Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	_ T ²
		Derwent World Patent Index AN 97-527238 & CN 1 126 589 (17 July 1996)	

Examiner	Date	1
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.